January 1, 2023International Journal of Heart Failure175 citationsOpen Access
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Structured PICO
Do SGLT-2 inhibitors reduce adverse cardiovascular outcomes in patients with heart failure across the ejection fraction spectrum?
P
Population
Patients with heart failure across the ejection fraction spectrum (reduced, mildly reduced, and preserved), type 2 diabetes, and chronic kidney disease
I
Intervention
SGLT-2 inhibitors
This review highlights the evolution of SGLT-2 inhibitors from metabolic drugs to foundational, guideline-directed therapies for heart failure across all ejection fractions, type 2 diabetes, and chronic kidney disease.
Abstract
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with recent trials suggesting a significant reduction in adverse cardiovascular outcomes in patients with HF with mildly reduced and preserved ejection fraction. SGLT-2 inhibitors have evolved as metabolic drugs due to their multi-system effects and are indicated for the management of HF across the ejection fraction spectrum, type 2 diabetes, and chronic kidney disease. There is ongoing research to explore the mechanistic effects of SGLT-2 inhibitors in HF and to evaluate their use in worsening HF and after myocardial infarction. This review focuses on the evidence for SGLT-2 inhibitors from type 2 diabetes cardiovascular outcome and primary HF trials and discusses ongoing research related to their use in cardiovascular disease.